jrnl232

Publication Venue For

  • Clinical and genetic risk prediction of cognitive impairment after blood or marrow transplantation for hematologic malignancy.  38:1312-1321. 2020
  • Clinical Cancer Advances 2020: Annual report on progress against cancer from the American Society of Clinical oncology.  38:1081-1101. 2020
  • MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trial.  38:1059-1069. 2020
  • Forging a new frontier: Providing palliative care to people with cancer in rural and remote areas.  38:963-973. 2020
  • Outcome in children with standard-risk b-cell acute lymphoblastic leukemia: Results of children's oncology group trial aall0331.  38:602-612. 2020
  • Impact of travel time on health care costs and resource use by phase of care for older patients with cancer.  37:1935-1945. 2019
  • Bridging the data-free zone: Decision making for older adults with cancer.  37:3469-3472. 2019
  • Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: A report from children's oncology group.  37:780-789. 2019
  • Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma.  37:3446-3454. 2019
  • Subsequent neoplasms after a primary tumor in individuals with neurofibromatosis type 1.  37:3050-3058. 2019
  • Survival by race and ethnicity in pediatric and adolescent patients with hodgkin lymphoma: A children’s oncology group study.  37:3009-3017. 2019
  • Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era.  37:471-480. 2019
  • End-of-life care intensity in patients undergoing allogeneic hematopoietic cell transplantation: A population-level analysis.  36:3023-3030. 2018
  • Should we be talking about guidelines with patients? A qualitative analysis in metastatic breast cancer..  36:217-217. 2018
  • Trust but verify: Patterns of obtaining health information and the role of physician trust in decision-making amongst patients with metastatic breast cancer..  36:218-218. 2018
  • Improved survival for children and young adults with t-lineage acute lymphoblastic leukemia: Results from the children's oncology Group AALL0434 methotrexate randomization.  36:2926-2934. 2018
  • Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome–positive acute lymphoblastic leukemia: Results of children’s oncology group trial AALL0622.  36:2306-2313. 2018
  • Surveillance for late effects in childhood cancer survivors.  36:2216-2222. 2018
  • Reply to E. Parkin et al.  36:2133-2134. 2018
  • New-onset cardiovascular morbidity in older adults with stage i to III colorectal cancer.  36:609-616. 2018
  • TP53 germline variations influence the predisposition and prognosis of b-cell acute lymphoblastic leukemia in children.  36:591-599. 2018
  • Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: Results from a prospective longitudinal study.  36:463-475. 2018
  • What is the role of symptom management and patient-reported outcomes in adherence to aromatase inhibitors?.  36:308-309. 2018
  • Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: A randomized controlled trial.  36:875-883. 2018
  • Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma.  36:859-866. 2018
  • Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer.  35:4057-4065. 2017
  • Prevalence and predictors of sperm banking in adolescents newly diagnosed with cancer: Examination of adolescent, parent, and provider factors influencing fertility preservation outcomes.  35:3830-3836. 2017
  • Clinical and genetic risk prediction of subsequent CNS tumors in survivors of childhood cancer: A report fromthe COG ALTE03N1 study.  35:3688-3696. 2017
  • Factors associated with participating in formal support services among family caregivers of older adults with poor-prognosis cancers..  35:21-21. 2017
  • Human papillomavirus vaccination rates in young cancer survivors.  35:3582-3590. 2017
  • Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: Report from the children’s oncology group phase III historically controlled trial AAML0631.  35:3021-3029. 2017
  • Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north American intergroup study swog s1117.  35:2745-2753. 2017
  • Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: A report from the Children’s Oncology Group.  35:2527-2534. 2017
  • Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute Lymphoblastic Leukemia: A report from the children’s Oncology group study AALL03N1.  35:1730-1736. 2017
  • Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma.  35:1598-1605. 2017
  • Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: A trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).  35:885-892. 2017
  • High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.  35:394-401. 2017
  • Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial.  35:56-62. 2017
  • Comprehensive geriatric assessment-guided therapy does improve outcomes of older patients with advanced lung cancer.  34:4047-4048. 2016
  • Differences between women’s preferred and actual experience with ‘shared decision-making’: A mixed method study..  34:34-34. 2016
  • Differences in self-care behaviors by varying levels of caregiving intensity, performance, and well-being among family caregivers of patients with high-mortality cancer..  34:239-239. 2016
  • What’s in the ‘special sauce’ of protocol-driven outpatient palliative care consultations?.  34:139-139. 2016
  • Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup consortium.  34:3440-3450. 2016
  • Changes in clinical context for Kaposi's sarcoma and non-Hodgkin lymphoma among people with HIV infection in the United States.  34:3276-3283. 2016
  • Reply to F. Felix et al and M.F. Fay et al.  34:3107-3108. 2016
  • Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis.  34:2468-2477. 2016
  • Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: A report from children's oncology group study AALL0232.  34:2380-2388. 2016
  • Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.  34:2359-2365. 2016
  • Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome.  34:1864-1871. 2016
  • Cardiovascular disease risk profiles in survivors of adolescent and young adult (AYA) cancer: The kaiser permanente AYA cancer survivors study.  34:1626-1633. 2016
  • Racial/ethnic differences in adverse outcomes among childhood cancer survivors: The childhood cancer survivor study.  34:1634-1643. 2016
  • Association of Human Papillomavirus and p16 Status with Outcomes in the IMCL-9815 Phase III Registration Trial for Patients with Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated with Radiotherapy with or Without Cetuximab.  34:1300-1308. 2016
  • Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study.  34:1122-1130. 2016
  • Final Results of the Sunbelt Melanoma trial: A multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy.  34:1079-1086. 2016
  • Reply to W. Hryniuk et al.  34:1153. 2016
  • Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: A report from the childhood cancer survivor study.  34:910-918. 2016
  • CELF4 variant and anthracycline-related cardiomyopathy: A children's oncology group genome-wide association study.  34:863-870. 2016
  • Chemotherapy for muscle-invasive bladder cancer: Better late than never?.  34:780-785. 2016
  • Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma.  34:731-739. 2016
  • A right atrial mass: "more than meets the eye".  34:e49-e50. 2016
  • Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression..  34:321-321. 2016
  • Changes in biomarkers and DNA methylation in breast cancer survivors enrolled in the ENERGY weight loss trial: A pilot study..  34:181. 2016
  • Physical activity communication between oncology providers and patients with early stage breast, colon or prostate cancer..  34:171-171. 2016
  • Vascular tumor burden as a new quantitative CT imaging biomarker for predicting metastatic RCC response to antiangiogenic therapy..  34:595-595. 2016
  • Reply to R.A. Ferrer et al and B.W. Corn.  33:4230-4231. 2015
  • Impact of tailored education on awareness of personal risk for therapy-related complications among childhood cancer survivors.  33:3887-3893. 2015
  • Recommendations for obesity clinical trials in cancer survivors: American Society of Clinical Oncology statement.  33:3961-3967. 2015
  • Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study.  33:3741-3749. 2015
  • Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors.  33:3186-3192. 2015
  • Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: A behavioral weight loss intervention in overweight or obese breast cancer survivors.  33:3169-3176. 2015
  • Trends toward declining aggressive care at end of life among older cancer patients in the Deep South 2015
  • Collaborative research in childhood cancer survivorship: The current landscape.  33:3055-3064. 2015
  • Late mortality after dexrazoxane treatment: A report from the Children's Oncology Group.  33:2639-2645. 2015
  • Reduction in late mortality among 5-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)..  33:LBA2. 2015
  • Disparities in hospice use among patients with cancer in the Deep South 2015
  • Identifying sources of distress in patients with breast cancer 2015
  • EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB - Expressing breast cancer.  33:1609-1619. 2015
  • Fewer scans, better care.  33:1624. 2015
  • Long-term pulmonary function in survivors of childhood cancer.  33:1592-1600. 2015
  • Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: Outcomes from the ENABLE III randomized controlled trial.  33:1446-1452. 2015
  • Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial.  33:1438-1445. 2015
  • Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.  33:1235-1242. 2015
  • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.  33:1252-1257. 2015
  • Benefits of Early versus Later Palliative Care to Informal Family Caregivers of Persons with Advanced Cancer: Outcomes from the ENABLE III Randomized Clinical Trial. 2015
  • Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: Results from children's oncology group study AALL07P4.  32:3874-3882. 2014
  • Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.  32:3840-3847. 2014
  • Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.  32:3619-3625. 2014
  • American Society of Clinical Oncology position statement on obesity and cancer.  32:3568-3574. 2014
  • Guiding lay navigation using the distress thermometer..  32:195. 2014
  • Impact of care at NCI Comprehensive Cancer Centers (NCICCC) on cancer outcome: Results from a population-based study..  32:188. 2014
  • Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation.  32:3249-3256. 2014
  • Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.  32:2940-2950. 2014
  • Breast cancer after chest radiation therapy for childhood cancer.  32:2217-2223. 2014
  • Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia intergroup trial E1905.  32:1242-1248. 2014
  • Cytogenetic prognostication within medulloblastoma subgroups.  32:886-896. 2014
  • Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: A report from the children's oncology group.  32:647-653. 2014
  • Immediate vs delayed initiation of concurrent palliative oncology care: Patient outcomes of the ENABLE III randomized controlled trial 2014
  • Epigenetics meets genetics in acute myeloid leukemia: Clinical impact of a novel seven-gene score.  32:548-556. 2014
  • Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales - A report from the Children's Oncology Group.  32:527-534. 2014
  • Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality.  32:273-281. 2014
  • Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC)..  32:409-409. 2014
  • Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC)..  32:383-383. 2014
  • Association between the prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer: A report from the st jude lifetime cohort study.  31:4242-4251. 2013
  • Impact of care at NCI comprehensive cancer centers (NCICCC) on outcomes in children, adolescents, and young adults (AYA) with central nervous system tumors (CNSt)..  31:123. 2013
  • Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: A report from the children's oncology group.  31:3397-3402. 2013
  • Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.  31:3212-3218. 2013
  • Hematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma.  31:3100-3109. 2013
  • Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.  31:2927-2935. 2013
  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study..  31:LBA2009. 2013
  • Reply to K. Orendi et al.  31:2361-2362. 2013
  • Clinical role of micrornas in cytogenetically normal acute myeloid leukemia: MiR-155 Upregulation independently identifies high-risk patients.  31:2086-2093. 2013
  • To your health: How does the latest research on alcohol and breast cancer inform clinical practice?.  31:1917-1919. 2013
  • Patient benefit from salvage radiation for prostate cancer..  31:175. 2013
  • American society of clinical oncology statement: Achieving high-quality cancer survivorship care.  31:631-640. 2013
  • Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC): Is preoperative chemoradiation (CRT) essential?.  31:236-236. 2013
  • Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma..  31:177-177. 2013
  • Quality of life among long-term survivors of non-Hodgkin lymphoma: A follow-up study.  31:272-279. 2013
  • A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer.  31:527-527. 2013
  • An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer.  31. 2013
  • Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.  30:4515-4523. 2012
  • Yield of Screening for Long-Term Complications Using the Children's Oncology Group Long-Term Follow-Up Guidelines.  30:4401-4408. 2012
  • The effect of care at NCI comprehensive cancer centers on disparities in outcome in adolescents and young adults (AYAs) with cancer..  30:217. 2012
  • Failure to rescue as a source of variation in hospital mortality for ovarian cancer.  30:3976-3982. 2012
  • Troublesome symptoms in cancer survivors: Fatigue, insomnia, neuropathy, and pain.  30:3687-3696. 2012
  • Reply to C.D. Atkins.  30:3563-3564. 2012
  • Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657.  30:3242-3249. 2012
  • Reply to M.C. Chamberlain et al.  30:3316-3317. 2012
  • RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures.  30:3109-3118. 2012
  • Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis.  30:2788-2797. 2012
  • Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children's oncology group.  30:2545-2551. 2012
  • Reach out to enhance wellness home-based diet-exercise intervention promotes reproducible and sustainable long-term improvements in health behaviors, body weight, and physical functioning in older, overweight/obese cancer survivors.  30:2354-2361. 2012
  • New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study..  30:CRA9513. 2012
  • Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: A report from the Children's Oncology Group.  30:2094-2101. 2012
  • Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.  30:2102-2111. 2012
  • Anthracycline-related cardiomyopathy after childhood cancer: Role of polymorphisms in carbonyl reductase genes - A report from the Children's Oncology Group.  30:1415-1421. 2012
  • Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.  30:742-750. 2012
  • Reply to J. Lagro et al.  30:561-562. 2012
  • Neoadjuvant interferon-based chemoradiation for locally advanced pancreas cancer: A phase II pilot study..  30:266. 2012
  • Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer..  30:362-371. 2012
  • Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.  30:419-425. 2012
  • Hormone receptor expression and risk of recurrence in patients with high-risk endometrial carcinoma treated with chemotherapy.  30:e15502-e15502. 2012
  • Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue.  29:4620-4626. 2011
  • Post-traumatic stress symptoms in long-term non-Hodgkin's lymphoma survivors: Does time heal?.  29:4526-4533. 2011
  • Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data..  29:4401-4409. 2011
  • Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.  29:3877-3884. 2011
  • An update on the dosimetric analysis of concurrent radiation therapy and trastuzumab on early cardiac events..  29:121. 2011
  • Treatment-related changes in neurobehavioral symptoms..  29:167. 2011
  • Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study.  29:3457-3465. 2011
  • Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: A report from the childhood cancer survivor study.  29:3056-3064. 2011
  • Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232..  29:3. 2011
  • Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.  29:2312-2318. 2011
  • A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma..  29:2010. 2011
  • Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer..  29:e11048. 2011
  • Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with Radiation Therapy (RTOG 9003).  29:1326-1334. 2011
  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A cancer and leukemia group B study.  29:1373-1381. 2011
  • Efficacy and rectal toxicity of hypofractionated radiation therapy with daily image guidance..  29:85. 2011
  • The reality of pancreas cancer care from access to delivery..  29:241. 2011
  • Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Primary analysis of Radiation Therapy Oncology Group study RTOG 0214.  29:272-278. 2011
  • Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis.  29:279-286. 2011
  • Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and mll gene rearrangements: A report from the children's oncology group.  29:214-222. 2011
  • Racial and ethnic disparities in risk and survival in children with neuroblastoma: A children's oncology group study.  29:76-82. 2011
  • Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  28:5257-5264. 2010
  • Capacity to consent to research participation in adults with malignant glioma.  28:3844-3850. 2010
  • IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  28:2348-2355. 2010
  • Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.  28:1749-1755. 2010
  • Favorable Prognostic Impact of NPM1 Mutations in Older Patients with Cytogenetically Normal de Novo Acute Myeloid Leukemia and Associated Gene- And MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study.  28:596-604. 2010
  • Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.  28:549-555. 2010
  • Improved early event-free survival with imatinib in Philadelphia chromosome - Positive acute lymphoblastic leukemia: A Children's Oncology Group Study.  27:5175-5181. 2009
  • Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.  27:5023-5030. 2009
  • High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses.  27:4754-4759. 2009
  • Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer.  27:4339-4345. 2009
  • Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  27:3198-3204. 2009
  • A phase I evaluation of intravenous (IV) (131)I-chlorotoxin delivery to solid peripheral and intracranial tumors..  27:e14507. 2009
  • A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects..  27:2041. 2009
  • A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme..  27:2023. 2009
  • A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients..  27:2536. 2009
  • Challenges for retrospective cohort studies: A profile of patients who refuse participation or are lost to follow-up..  27:6615. 2009
  • Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States..  27:2003. 2009
  • Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis..  27:6027. 2009
  • Differential survival after prostate cancer by race: Role of NCI-designated comprehensive cancer centers..  27:6520. 2009
  • Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma..  27:e13006. 2009
  • Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma..  27:2039. 2009
  • In vitro chemoresponse assay results and population chemotherapy response rates in endometrial cancer..  27:5503. 2009
  • NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM)..  27:2001. 2009
  • NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM)..  27:2010. 2009
  • Prognostic significance of VDR, DKK-1, and DKK-4 expression in colorectal cancer..  27:e15047. 2009
  • Recommendation of adjuvant chemotherapy and trastuzumab in older adults with HER2-positive breast cancer: A survey of oncologists..  27:9547. 2009
  • Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme..  27:2028. 2009
  • Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results..  27:2042. 2009
  • Health behaviors influence cancer survival.  27:1930-1932. 2009
  • Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.  27:791-798. 2009
  • Late congestive heart failure after hematopoietic cell transplantation.  26:5537-5543. 2008
  • Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.  26:5610-5617. 2008
  • Reirradiation and concurrent chemotherapy after salvage surgery: Pay now or pay later.  26:5500-5501. 2008
  • Role of age and health in treatment recommendations for older adults with breast cancer: The perspective of oncologists and primary care providers.  26:5386-5392. 2008
  • Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma.  26:5297-5299. 2008
  • Prognostic significance of, and gene and MicroRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A cancer and leukemia group B study.  26:5078-5087. 2008
  • Phase II trial of sorafenib in advanced thyroid cancer.  26:4714-4719. 2008
  • Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  26:4595-4602. 2008
  • Effect of molecular therapeutics on liver regeneration in a murine model.  26:1836-1842. 2008
  • Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.  26:2489-2496. 2008
  • Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model..  26:14695. 2008
  • Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.  26. 2008
  • Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.  26:897-906. 2008
  • Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the children's oncology group.  26:633-638. 2008
  • Move onward, press forward, and take a deep breath: Can lifestyle interventions improve the quality of life of women with breast cancer, and how can we be sure?.  25:4344-4345. 2007
  • Biology of interactions: Antiepidermal growth factor receptor agents.  25:4057-4065. 2007
  • High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study.  25:3337-3343. 2007
  • Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).  25:3124-3129. 2007
  • Main outcomes of the FRESH START trial: A sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors.  25:2709-2718. 2007
  • Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.  25:2191-2197. 2007
  • Lessons learned in the management of advanced pancreatic cancer.  25:1949-1952. 2007
  • Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.  25:1651-1657. 2007
  • Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators.  25:669-674. 2007
  • Interpreting the economic literature in oncology.  25:196-202. 2007
  • Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology.  25:146-162. 2007
  • Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed high-grade gliomas.  24:5419-5426. 2006
  • Promoting health and physical function among cancer survivors: Potential for prevention and questions that remain.  24:5125-5131. 2006
  • Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.  24:5025-5033. 2006
  • Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group.  24:4738-4745. 2006
  • Disadvantage of men living alone participating in radiation therapy oncology group head and neck trials.  24:4177-4183. 2006
  • Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study.  24:3904-3911. 2006
  • Cancer survival: Time to get moving? Data accumulate suggesting a link between physical activity and cancer survival.  24:3517-3518. 2006
  • Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.  24:3644-3650. 2006
  • Lifestyle intervention development study to improve physical function in older adults with cancer: Outcomes from project LEAD.  24:3465-3473. 2006
  • Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy.  24:2978-2980. 2006
  • A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth..  24:11505. 2006
  • An IMRT technique to increase therapeutic ratio of breast irradiation in patients with early stage left breast cancer: Limiting second malignancies..  24:10791. 2006
  • Effects of depression on quality of life in Medicare beneficiaries with prostate cancer..  24:8510. 2006
  • Ex vivo activation and expansion of γδ T cells for immunotherapy of glioblastoma..  24:2553. 2006
  • Phenotypic expression of Bax is a predictive marker of 5-fluorouracil treatment in colorectal cancer..  24:3605. 2006
  • Polymorphisms in candidate genes in patients with congestive heart failure (CHF) after childhood cancer: A Report from the Childhood Cancer Survivor Study (CCSS)..  24:9004. 2006
  • Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.  24:2849-2857. 2006
  • Results of FRESH START: A randomized controlled trial to improve diet and exercise behaviors in breast and prostate cancer survivors..  24:8503. 2006
  • Results of FRESH START: A randomized controlled trial to improve diet and exercise behaviors in breast and prostate cancer survivors..  24:468S-468S. 2006
  • Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer..  24:10622. 2006
  • Safety and tolerance of multiple weekly intracavitary injections of 131I-chlorotoxin (TM-601): Preliminary results of a prospective clinical trial in patients with recurrent glioblastoma multiforme..  24:1555. 2006
  • Solid organ second malignant neoplasms among children diagnosed with malignant bone tumors treated on Children Cancer Study Group/Pediatric Oncology Group protocols after 1980..  24:9007. 2006
  • Tumor necrosis factor-α-induced protein 3 down-regulates nuclear factor-κB-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas..  24:1508. 2006
  • Use of complementary and alternative medicine and spiritual practices among women with ovarian carcinoma in the southeastern United States..  24:15048. 2006
  • Visual complications in childhood cancer survivors: A Childhood Cancer Survivor Study report..  24:9006. 2006
  • Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.  24:2456-2464. 2006
  • Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit.  24:2298-2303. 2006
  • Impact of IGF-I and CYP19 Gene Polymorphisms on the Survival of Patients With Metastatic Prostate Cancer.  24:1982-1989. 2006
  • Is it time to abandon microsatellite instability as a pre-screen for selecting families for mutation testing for mismatch repair genes? [5].  24:1960-1962. 2006
  • Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomas.  24:274-287. 2006
  • Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14.  23:3008-3015. 2005
  • In reply [2].  23:9428. 2005
  • Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.  23:2004-2011. 2005
  • Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B study.  23:482-493. 2005
  • Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study.  23:9234-9242. 2005
  • Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of genes related to outcome.  23:8679-8687. 2005
  • Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer.  23:9089-9096. 2005
  • Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study.  23:5705-5717. 2005
  • Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy.  23:4399-4405. 2005
  • Riding the crest of the teachable moment: Promoting long-term health after the diagnosis of cancer.  23:5814-5830. 2005
  • Uncommon malignancies: Case 2. Gastric choriocarcinoma.  23:6251-6253. 2005
  • Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.  23:6699-6711. 2005
  • Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.  23:6664-6673. 2005
  • Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety.  23:6730-6738. 2005
  • Feasibility of hand-assisted laparoscopic surgery (HALS) in gynecologic oncology patients..  23:5153. 2005
  • Results of Project LEAD (Leading the Way in Exercise and Diet) - A trial testing an intervention of telephone-counseling and mailed materials in improving physical functioning among older breast and prostate cancer survivors.  23:763S-763S. 2005
  • Results of Project LEAD (Leading the Way in Exercise and Diet) - A trial testing an intervention of telephone-counseling and mailed materials in improving physical functioning among older breast and prostate cancer survivors..  23:8138. 2005
  • TRAIL death receptor therapy for malignant glioma..  23:3187. 2005
  • TRAIL-mediated induction of apoptosis as a targeted therapy for prostate cancer..  23:3186. 2005
  • Development of risk-based guidelines for pediatric cancer survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.  22:4979-4990. 2004
  • Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: Results from Cancer and Leukemia Group B study 8461.  22:2410-2418. 2004
  • Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose Control in PNU-214936.  22:602-609. 2004
  • Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.  22:2856-2864. 2004
  • Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461.  22:1087-1094. 2004
  • Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.  22:1063-1070. 2004
  • Understanding cancer treatment and outcomes: The cancer care outcomes research and surveillance consortium.  22:2992-2996. 2004
  • Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging..  22:742. 2004
  • Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients..  22:5044. 2004
  • Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy..  22:5083. 2004
  • UAB's experience with concurrent capecitabine (CAP) and radiotherapy (RT) in Pts with resected (RES) or locally advanced (LA) pancreatic cancer (Pan Ca)..  22:4188. 2004
  • High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group.  21:4386-4394. 2003
  • Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.  21:4314-4321. 2003
  • Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.  21:3512-3519. 2003
  • The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.  21:3201-3206. 2003
  • The Minneapolis-Manchester quality of life instrument: Reliability and validity of the adolescent form.  20:4692-4698. 2002
  • Revision of the American Joint Committee on cancer staging system for breast cancer.  20:3628-3636. 2002
  • Nutrition and survival after the diagnosis of breast cancer: A review of the evidence.  20:3302-3316. 2002
  • Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.  20:3262-3269. 2002
  • Adjuvant radiation therapy after complete resection of non-small-cell lung cancer [3] (multiple letters).  20:1427-1429. 2002
  • Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial.  20:426-433. 2002
  • Neuropsychologic impact of standard dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma 2002
  • Balancing the possible effectiveness of postoperative radiotherapy for non-small-cell lung cancer against the possible detriment of radiation-induced toxicity.  19:3905-3907. 2001
  • Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.  19:3918-3928. 2001
  • Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system.  19:3622-3634. 2001
  • Is there an association between total-body irradiation and secondary acute myelogenous leukemia/myelodysplastic syndrome in patients with relapsed/refractory Hodgkin's disease treated with autologous stem-cell transplantation? [2] (multiple letters).  19:3585-3588. 2001
  • Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.  19:3234-3243. 2001
  • Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy.  19:2381-2389. 2001
  • Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: A cancer and leukemia group B study.  19:2482-2492. 2001
  • Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.  19:2171-2178. 2001
  • Solid cancers after bone marrow transplantation.  19:464-471. 2001
  • BR96-doxorubicin: Been there, done that! [1] (multiple letters).  18:4000. 2000
  • Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers..  18:47S-53S. 2000
  • Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.  18:1316-1323. 2000
  • Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors.  18:2282-2292. 2000
  • Massage therapy for patients undergoing autologous bone marrow transplant 1999
  • Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.  17:2681-2691. 1999
  • Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer.  17:478-484. 1999
  • Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) Translocation.  17:191-196. 1999
  • Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.  17:3767-3775. 1999
  • Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.  17:268-276. 1999
  • Consolidation therapy with antimetabolite-based therapy in standard- risk acute lymphocytic leukemia of childhood: A pediatric oncology group study.  16:2840-2847. 1998
  • Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.  16:3246-3256. 1998
  • Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease.  16:818-829. 1998
  • Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A pediatric oncology group study.  16:2854-2863. 1998
  • Second cancers after pediatric Hodgkin's disease [2] (multiple letters).  16:2570-2572. 1998
  • Assessment of genomic damage in colorectal cancer by DNA fingerprinting: Prognostic applications.  15:3230-3240. 1997
  • Association of local recurrence with subsequent survival in extremity soft tissue sarcoma.  15:646-652. 1997
  • Brain tumor-polyposis syndrome: Two genetic diseases?.  15:2744-2758. 1997
  • Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from Cancer and Leukemia Group B 8461.  15:466-475. 1997
  • Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study.  15:901-907. 1997
  • Phase II trial of docetaxel in non-Hodgkin's lymphomas: A study of the cancer and leukemia group B.  15:3275-3279. 1997
  • Prognostic factors associated with long-term survival for retroperitoneal sarcoma: Implications for management.  15:2832-2839. 1997
  • Secondary cytogenetic changes in acute promyelocytic leukemia - Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A Cancer and Leukemia Group B study.  15:1786-1795. 1997
  • Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer.  14:2322-2330. 1996
  • Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: A Pediatric Oncology Group study.  14:1252-1261. 1996
  • Prognostic significance of a positive microscopic margin in high-risk extremity soft tissue sarcoma: Implications for management.  14:473-478. 1996
  • Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.  14:18-24. 1996
  • Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.  13:1384-1390. 1995
  • Effect of a National Cancer Institute Clinical Alert on breast cancer practice patterns.  12:1783-1788. 1994
  • Limited-stage small-cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy.  12:496-502. 1994
  • Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.  12:1890-1901. 1994
  • Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: A randomized trial of the southeastern cancer study group.  11:1223-1229. 1993
  • Immunophenotypes and karyotypes of leukemic cells in children with down syndrome and acute lymphoblastic leukemia.  11:1361-1367. 1993
  • Stage III neuroblastoma over 1 year of age at diagnosis: Improved survival with intensive multimodality therapy including multiple alkylating agents.  11:84-90. 1993
  • Why women gain weight with adjuvant chemotherapy for breast cancer.  11:1418-1429. 1993
  • Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. The CNS Cancer Consortium..  10:452-458. 1992
  • A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study.  10:1103-1111. 1992
  • Ploidy of lymphoblasts is the strongest predictor of treatment outcome in b-progenitor cell acute lymphoblastic leukemia of childhood: A pediatric oncology group study.  10:606-613. 1992
  • Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas.  10:452-458. 1992
  • Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study.  10:249-256. 1992
  • Corynebacterium parvum versus bacille calmette-guérin adjuvant immunotherapy of stage II malignant melanoma.  9:1151-1156. 1991
  • Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: A pediatric oncology group study.  8:1389-1398. 1990
  • Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: A Southeastern Cancer Study Group trial.  8:886-891. 1990
  • Phase II treatment of medulloblastoma and pineoblastoma with melphalan: Clinical therapy based on experimental models of human medulloblastoma.  7:904-911. 1989
  • A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.  6:1397-1400. 1988
  • Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma.  6:1059-1065. 1988
  • Consolidation and maintenance therapy in multiple myeloma: Randomized comparison of a new approach to therapy after initial response to treatment.  4:888-899. 1986
  • Ewing's sarcoma in bones of the hands and feet: A clinicopathologic study and review of the literature.  3:686-697. 1985
  • Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: A Southeastern Cancer Study Group Trial.  3:1188-1195. 1985
  • Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: A Southeastern Cancer Study Group trial.  2:391-395. 1984
  • A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma..  1:720-726. 1983